[go: up one dir, main page]

AR092439A1 - Composicion farmaceutica recubierta que contiene regorafenib - Google Patents

Composicion farmaceutica recubierta que contiene regorafenib

Info

Publication number
AR092439A1
AR092439A1 ARP130103145A ARP130103145A AR092439A1 AR 092439 A1 AR092439 A1 AR 092439A1 AR P130103145 A ARP130103145 A AR P130103145A AR P130103145 A ARP130103145 A AR P130103145A AR 092439 A1 AR092439 A1 AR 092439A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
regorafenib
pharmaceutically acceptable
polyvinyl alcohol
coating
Prior art date
Application number
ARP130103145A
Other languages
English (en)
Inventor
Skrabs Susanne
Dr Funke Adrian
Dr Kresse Mayk
Dr Oberdieck Ulrich
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR092439(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of AR092439A1 publication Critical patent/AR092439A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893Tablet coating processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica que comprende regorafenib, un hidrato, solvato, metabolito o sal farmacéuticamente aceptable de regorafenib, o un polimorfo del mismo y al menos un excipiente farmacéuticamente aceptable, en el que la composición farmacéutica está recubierta por un recubrimiento que comprende un polímero basado en alcohol polivinílico y opcionalmente uno o más excipientes adicionales farmacéuticamente aceptables. Reivindicación 5: La composición de la reivindicación 4, en la que el polímero basado en alcohol polivinílico es un polímero de alcohol polivinílico parcialmente hidrolizado. Reivindicación 18: Procedimiento para la fabricación de una composición farmacéutica recubierta con película que comprende regorafenib, en el que el líquido de recubrimiento es pulverizado sobre la composición farmacéutica en una cubeta o en un recubridor de tambor perforado y la temperatura del aire de salida durante el recubrimiento es igual a, o inferior a 42ºC.
ARP130103145A 2012-09-06 2013-09-04 Composicion farmaceutica recubierta que contiene regorafenib AR092439A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12183331 2012-09-06

Publications (1)

Publication Number Publication Date
AR092439A1 true AR092439A1 (es) 2015-04-22

Family

ID=46963450

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103145A AR092439A1 (es) 2012-09-06 2013-09-04 Composicion farmaceutica recubierta que contiene regorafenib

Country Status (43)

Country Link
US (1) US20140065212A1 (es)
EP (2) EP2892507B1 (es)
JP (1) JP6445436B2 (es)
KR (1) KR102162036B1 (es)
CN (5) CN111249247A (es)
AP (1) AP2015008292A0 (es)
AR (1) AR092439A1 (es)
AU (1) AU2013312531B2 (es)
BR (1) BR112015004936B1 (es)
CA (1) CA2883767C (es)
CL (1) CL2015000544A1 (es)
CO (1) CO7310528A2 (es)
CR (1) CR20150114A (es)
CU (1) CU24244B1 (es)
CY (1) CY1118839T1 (es)
DK (1) DK2892507T3 (es)
EA (1) EA027685B1 (es)
ES (1) ES2623205T3 (es)
GT (1) GT201500053A (es)
HK (1) HK1214170A1 (es)
HR (1) HRP20170620T1 (es)
HU (1) HUE032758T2 (es)
IL (1) IL237350B (es)
IN (1) IN2015DN01673A (es)
JO (1) JO3479B1 (es)
LT (1) LT2892507T (es)
MA (1) MA37888B1 (es)
MX (1) MX359922B (es)
MY (1) MY176135A (es)
NZ (1) NZ705578A (es)
PE (1) PE20151005A1 (es)
PH (1) PH12015500460B1 (es)
PL (1) PL2892507T3 (es)
PT (1) PT2892507T (es)
RS (1) RS56019B1 (es)
SA (1) SA515360113B1 (es)
SG (1) SG11201501683WA (es)
SI (1) SI2892507T1 (es)
TW (1) TWI640329B (es)
UA (1) UA115994C2 (es)
UY (1) UY35006A (es)
WO (1) WO2014039677A1 (es)
ZA (1) ZA201501394B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
US20160220494A1 (en) * 2013-09-13 2016-08-04 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
CN104586808B (zh) * 2014-12-27 2017-08-18 北京元延医药科技股份有限公司 抗肿瘤药物组合物
CN105136956A (zh) * 2015-09-11 2015-12-09 江苏嘉逸医药有限公司 一种快速测定瑞戈非尼含量的方法
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CN106880607A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种含有瑞戈非尼的口腔崩解片及其制备方法
CN106880615A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种瑞戈非尼的口服固体制剂及其制备方法
CN105496975B (zh) * 2015-12-17 2019-01-04 河南润弘制药股份有限公司 一种瑞戈非尼片剂及其制备方法
CN106913527A (zh) * 2015-12-28 2017-07-04 江苏先声药业有限公司 一种瑞戈非尼速释微丸及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
CN107661296A (zh) * 2016-07-27 2018-02-06 江苏先声药业有限公司 一种瑞戈非尼固体分散体及其制备方法
IL270948B2 (en) * 2017-06-02 2025-07-01 Bayer Ag Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
CN112367995A (zh) * 2018-07-06 2021-02-12 安吉奥斯医药品有限公司 艾伏尼布形式和药物组合物
CN111053751A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 瑞戈非尼的缓释片剂及其制备方法
TWI799599B (zh) * 2019-06-06 2023-04-21 華納國際生物科技股份有限公司 醫藥或保健品自乳化固體分散組成物
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
CN112587485A (zh) * 2021-01-08 2021-04-02 湖南南新制药股份有限公司 一种药物固体分散体及其制备方法
CN113018274A (zh) * 2021-03-10 2021-06-25 药源生物科技(启东)有限公司 一种含羟丙甲纤维素的药物组合物及其制备方法
TR2023002707A2 (tr) * 2023-03-10 2024-09-23 Abdi̇ İbrahi̇m İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Regorafenib içeren bir farmasötik bileşim.
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100544717C (zh) * 2002-09-20 2009-09-30 华生制药公司 含有双胍和噻唑烷二酮衍生物的药物剂型
CN1265793C (zh) * 2002-11-18 2006-07-26 杭州容立医药科技有限公司 左西替利嗪伪麻黄碱复方口服制剂及制备方法
KR101139557B1 (ko) 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2007068381A1 (en) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl ureas for treating inflammatory skin, eye and/or ear diseases
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008044111A1 (en) * 2006-10-13 2008-04-17 Pfizer Products Inc. Pharmaceutical formulation tablet
EP2101767A2 (en) * 2006-12-07 2009-09-23 Eli Lilly & Company An article comprising prasugrel
CA2703365A1 (en) * 2007-10-25 2009-04-30 Yuka Yamanouchi Nifedipine-containing press coated tablet and method of preparing the same
AR081060A1 (es) * 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
KR20200003219A (ko) * 2011-05-20 2020-01-08 아스트라제네카 유케이 리미티드 로수바스타틴 칼슘의 약학 조성물

Also Published As

Publication number Publication date
HUE032758T2 (en) 2017-10-30
CN116392598A (zh) 2023-07-07
IL237350A0 (en) 2015-04-30
CU20150020A7 (es) 2015-05-28
UA115994C2 (uk) 2018-01-25
MY176135A (en) 2020-07-24
MX359922B (es) 2018-10-16
PE20151005A1 (es) 2015-06-27
SG11201501683WA (en) 2015-04-29
CA2883767A1 (en) 2014-03-13
MA37888A1 (fr) 2018-07-31
SI2892507T1 (sl) 2017-08-31
CU24244B1 (es) 2017-02-02
CY1118839T1 (el) 2018-01-10
LT2892507T (lt) 2017-06-12
MA37888B1 (fr) 2019-08-30
PL2892507T3 (pl) 2017-09-29
HRP20170620T1 (hr) 2017-06-30
AU2013312531B2 (en) 2017-10-19
EA201590520A1 (ru) 2015-10-30
TW201414510A (zh) 2014-04-16
IL237350B (en) 2020-11-30
HK1214170A1 (zh) 2016-07-22
PH12015500460A1 (en) 2015-04-20
AU2013312531A1 (en) 2015-03-12
KR102162036B1 (ko) 2020-10-07
CA2883767C (en) 2018-11-13
CN116392484A (zh) 2023-07-07
CL2015000544A1 (es) 2015-08-21
ZA201501394B (en) 2016-07-27
JP6445436B2 (ja) 2018-12-26
PH12015500460B1 (en) 2015-04-20
CR20150114A (es) 2015-05-11
BR112015004936B1 (pt) 2022-12-06
AP2015008292A0 (en) 2015-02-28
RS56019B1 (sr) 2017-09-29
CN116392485A (zh) 2023-07-07
EP2892507A1 (en) 2015-07-15
KR20150048872A (ko) 2015-05-07
US20140065212A1 (en) 2014-03-06
SA515360113B1 (ar) 2016-08-10
NZ705578A (en) 2017-10-27
CO7310528A2 (es) 2015-06-30
UY35006A (es) 2014-03-31
TWI640329B (zh) 2018-11-11
DK2892507T3 (en) 2017-05-01
EP2892507B1 (en) 2017-02-01
IN2015DN01673A (es) 2015-07-03
GT201500053A (es) 2015-10-12
EP3243508A1 (en) 2017-11-15
EA027685B1 (ru) 2017-08-31
PT2892507T (pt) 2017-05-02
CN104902878A (zh) 2015-09-09
CN111249247A (zh) 2020-06-09
MX2015002815A (es) 2015-05-15
JO3479B1 (ar) 2020-07-05
ES2623205T3 (es) 2017-07-10
WO2014039677A1 (en) 2014-03-13
BR112015004936A2 (pt) 2017-07-04
JP2015527395A (ja) 2015-09-17

Similar Documents

Publication Publication Date Title
AR092439A1 (es) Composicion farmaceutica recubierta que contiene regorafenib
EP2939979A4 (en) GRAPHIC OXIDE, GRAPHENE POLYMER COMPLEX, COATING SOLUTION THEREWITH, GRAPHENE POLYMER COATED STEEL PLATE AND METHOD OF MANUFACTURING THEREOF
UA115868C2 (uk) Гетероциклічні сполуки, лікарські засоби, які містять зазначені сполуки, їх застосування і способи їх одержання
EP2862883A4 (en) Method for producing nucleator masterbatch
DOP2013000314A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2013017910A8 (en) Extended release pharmaceutical compositions containing paliperidone
EA201301168A1 (ru) Аклидиний для применения при улучшении качества сна у пациентов с респираторными заболеваниями
AR097644A1 (es) Composiciones farmacéuticas que contienen refametinib, uso y método de tratamiento
GEP201706743B (en) Oral formulation for the treatment of cardiovascular diseases
JP2014518280A5 (es)
UA118008C2 (uk) Спосіб синтезу (2е)-3-(3,4-диметоксифеніл)проп-2-еннітрилу та застосування в синтезі івабрадину та його адитивних солей з фармацевтично прийнятною кислотою
EP2789604A4 (en) DAZEZE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT AND METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
UY35149A (es) Nuevo procedimiento de síntesis del 3 -(2-bromo-4,5-dimetoxifenil) propanonitrilo, y aplicación a la síntesis de la ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable
WO2015036972A3 (en) Selective dopamine d4 receptor agonists for treatment of working memory deficits
IN2014DE01203A (es)
UY35068A (es) Nuevo procedimiento de síntesis del 3-(2-bromo-4,5-dimetoxifenil)propanonitrilo, y aplicación a la síntesis de la ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable
DOP2015000049A (es) Composición farmacéutica recubierta que contiene regorafenib
JO3083B1 (ar) عملية جديدة لتخليق إيفابرادين وأملاحه المضافة مع حمض مقبول صيدلانيا
TH148556A (th) กระบวนการใหม่สำหรับการสังเคราะห์ของไอวาบราดีน (ivabradine) และ เกลือของมันจากการเติมด้วยกรดที่เป็นที่ยอมรับในทางเภสัชกรรม
PH22013000368U3 (en) A coating formulation for a tablet containing amino acid for chronic kidney disease
IL261618B (en) An immediate release dosage unit of ghb or one of its medically acceptable salts, administered orally and used to maintain abstinence from alcohol
WO2012102875A3 (en) Analgesic compounds, methods, and formulations
TH154932A (th) องค์ประกอบทางเภสัชกรรมซึ่งประกอบด้วย รีโกราเฟนิบ ที่ถูกเคลือบ
CL2007003806A1 (es) Compuestos derivados de n-(2h-pirazol-3-il)-amida, inhibidores del fgfr; composicion farmaceutica que comprende a dichos compuestos; su proceso de preparacion; y su uso para el tratamiento del cancer.

Legal Events

Date Code Title Description
FC Refusal